Global Newborn Screening for SMA and SCID Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch's in-depth investigation and research, the global Newborn Screening for SMA and SCID market size will reach 197.25 Million USD in 2025 and is projected to reach 403.62 Million USD by 2032, with a CAGR of 10.77% (2025-2032). Notably, the China Newborn Screening for SMA and SCID market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Newborn screening for Spinal Muscular Atrophy (SMA) and Severe Combined Immunodeficiency (SCID) involves testing newborn infants shortly after birth to detect these genetic disorders early on, even before symptoms appear. SMA is a genetic condition that affects the motor neurons, leading to muscle weakness and loss of movement. SCID is a rare, life-threatening condition that affects the immune system, leaving infants susceptible to severe infections. Screening for SMA involves identifying specific genetic markers or mutations associated with the condition. Similarly, SCID screening detects the absence or dysfunction of immune cells. Early detection of SMA and SCID allows for timely medical interventions, such as gene therapy, enzyme replacement therapy, or bone marrow transplantation, which can significantly improve outcomes and increase the chances of effective treatment. Newborn screening for SMA and SCID aims to ensure that affected infants receive appropriate medical care and support as early as possible, preventing complications and improving their quality of life.
The major global suppliers of Newborn Screening for SMA and SCID include Perkinelmer, Thermo Fisher, ImmunoIVD, Labsystems Diagnostics, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Newborn Screening for SMA and SCID. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Newborn Screening for SMA and SCID market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Newborn Screening for SMA and SCID market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Newborn Screening for SMA and SCID industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Newborn Screening for SMA and SCID Include:
Perkinelmer
Thermo Fisher
ImmunoIVD
Labsystems Diagnostics
Newborn Screening for SMA and SCID Product Segment Include:
Instruments
Kits
Software
Newborn Screening for SMA and SCID Product Application Include:
SCID Screening
SMA Screening
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Newborn Screening for SMA and SCID Industry PESTEL Analysis
Chapter 3: Global Newborn Screening for SMA and SCID Industry Porter's Five Forces Analysis
Chapter 4: Global Newborn Screening for SMA and SCID Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Newborn Screening for SMA and SCID Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Newborn Screening for SMA and SCID Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Newborn Screening for SMA and SCID Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch's in-depth investigation and research, the global Newborn Screening for SMA and SCID market size will reach 197.25 Million USD in 2025 and is projected to reach 403.62 Million USD by 2032, with a CAGR of 10.77% (2025-2032). Notably, the China Newborn Screening for SMA and SCID market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Newborn screening for Spinal Muscular Atrophy (SMA) and Severe Combined Immunodeficiency (SCID) involves testing newborn infants shortly after birth to detect these genetic disorders early on, even before symptoms appear. SMA is a genetic condition that affects the motor neurons, leading to muscle weakness and loss of movement. SCID is a rare, life-threatening condition that affects the immune system, leaving infants susceptible to severe infections. Screening for SMA involves identifying specific genetic markers or mutations associated with the condition. Similarly, SCID screening detects the absence or dysfunction of immune cells. Early detection of SMA and SCID allows for timely medical interventions, such as gene therapy, enzyme replacement therapy, or bone marrow transplantation, which can significantly improve outcomes and increase the chances of effective treatment. Newborn screening for SMA and SCID aims to ensure that affected infants receive appropriate medical care and support as early as possible, preventing complications and improving their quality of life.
The major global suppliers of Newborn Screening for SMA and SCID include Perkinelmer, Thermo Fisher, ImmunoIVD, Labsystems Diagnostics, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Newborn Screening for SMA and SCID. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Newborn Screening for SMA and SCID market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Newborn Screening for SMA and SCID market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Newborn Screening for SMA and SCID industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Newborn Screening for SMA and SCID Include:
Perkinelmer
Thermo Fisher
ImmunoIVD
Labsystems Diagnostics
Newborn Screening for SMA and SCID Product Segment Include:
Instruments
Kits
Software
Newborn Screening for SMA and SCID Product Application Include:
SCID Screening
SMA Screening
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Newborn Screening for SMA and SCID Industry PESTEL Analysis
Chapter 3: Global Newborn Screening for SMA and SCID Industry Porter's Five Forces Analysis
Chapter 4: Global Newborn Screening for SMA and SCID Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Newborn Screening for SMA and SCID Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Newborn Screening for SMA and SCID Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Newborn Screening for SMA and SCID Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Newborn Screening for SMA and SCID Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Newborn Screening for SMA and SCID Product by Type
- 1.2.1 Instruments
- 1.2.2 Kits
- 1.2.3 Software
- 1.3 Newborn Screening for SMA and SCID Product by Application
- 1.3.1 SCID Screening
- 1.3.2 SMA Screening
- 1.4 Global Newborn Screening for SMA and SCID Market Size Analysis (2020-2032)
- 1.5 Newborn Screening for SMA and SCID Market Development Status and Trends
- 1.5.1 Newborn Screening for SMA and SCID Industry Development Status Analysis
- 1.5.2 Newborn Screening for SMA and SCID Industry Development Trends Analysis
- 2 Newborn Screening for SMA and SCID Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Newborn Screening for SMA and SCID Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Newborn Screening for SMA and SCID Market Analysis by Country
- 4.1 Global Newborn Screening for SMA and SCID Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Newborn Screening for SMA and SCID Revenue Analysis by Country (2020-2025)
- 4.1.2 Global Newborn Screening for SMA and SCID Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 4.5 China Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 4.6 France Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 4.14 India Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa Newborn Screening for SMA and SCID Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global Newborn Screening for SMA and SCID Market Revenue by Key Suppliers (2021-2025)
- 5.2 Newborn Screening for SMA and SCID Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Newborn Screening for SMA and SCID Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Newborn Screening for SMA and SCID Market Analysis by Type
- 6.1 Global Newborn Screening for SMA and SCID Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global Newborn Screening for SMA and SCID Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Perkinelmer
- 7.1.1 Perkinelmer Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Perkinelmer Newborn Screening for SMA and SCID Product Portfolio
- 7.1.3 Perkinelmer Newborn Screening for SMA and SCID Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 Thermo Fisher
- 7.2.1 Thermo Fisher Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Thermo Fisher Newborn Screening for SMA and SCID Product Portfolio
- 7.2.3 Thermo Fisher Newborn Screening for SMA and SCID Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 ImmunoIVD
- 7.3.1 ImmunoIVD Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 ImmunoIVD Newborn Screening for SMA and SCID Product Portfolio
- 7.3.3 ImmunoIVD Newborn Screening for SMA and SCID Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 Labsystems Diagnostics
- 7.4.1 Labsystems Diagnostics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 Labsystems Diagnostics Newborn Screening for SMA and SCID Product Portfolio
- 7.4.3 Labsystems Diagnostics Newborn Screening for SMA and SCID Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 Newborn Screening for SMA and SCID Industry Chain Analysis
- 8.2 Newborn Screening for SMA and SCID Product Downstream Application Analysis
- 8.2.1 Global Newborn Screening for SMA and SCID Market Size and Growth Rate (CAGR) by Application: 2024 VS 2025 VS 2032
- 8.2.2 Global Newborn Screening for SMA and SCID Revenue and Forecast by Application (2020-2032)
- 8.3 Newborn Screening for SMA and SCID Typical Downstream Customers
- 8.4 Newborn Screening for SMA and SCID Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
